Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colesevelam + atorvastatin is a combination therapy used primarily for the management of hypercholesterolemia (high cholesterol). Colesevelam is a bile acid sequestrant that works by binding bile acids in the intestine, preventing their reabsorption and promoting their excretion. This process depletes the bile acid pool, leading to increased conversion of cholesterol to bile acids in the liver and upregulation of LDL receptors, which enhances clearance of LDL cholesterol from the blood[1][6][8]. Atorvastatin is an HMG-CoA reductase inhibitor (statin) that reduces cholesterol synthesis in the liver and also increases hepatic uptake of LDL cholesterol. The combination has been shown to be more effective at lowering LDL-C than either agent alone[5]. Colesevelam may also improve glycemic control in type 2 diabetes mellitus. The primary indication for this combination is hypercholesterolemia, especially when monotherapy with statins or colesevelam alone does not achieve target lipid levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on colesevelam + atorvastatin.